Irritable Bowel Syndrome Trial, Recruiting NCT07540312 Sponsor: PGP Health Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Irritable Bowel Syndrome Trial, Recruiting

NCT07540312
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a written consent form agreeing to take part in the trial.
  • You weigh at least 50 kg (about 110 lbs) and have a body mass index (BMI) between 18 and 40.
  • You have been diagnosed with Irritable Bowel Syndrome (IBS) — specifically the constipation type, diarrhea type, or mixed type — at a moderate to severe level, based on recognised medical guidelines called the Rome Criteria.

Who may not be able to join:

  • You have a known allergy to the device being tested or its components, or you have significant allergies (not including mild seasonal allergies like hay fever).
  • You have a significant medical history involving the digestive system, heart, muscles or joints, hormones, blood, kidneys, liver, lungs, nervous system, immune system, mental health, or cholesterol levels that could affect the trial or put you at risk (confirm with trial site).
  • You have been in hospital or had major surgery within the 30 days before screening.
  • You are pregnant or have a positive pregnancy test.
  • You have taken part in another clinical drug trial within the 30 days before screening.
  • You have a diagnosed problem with substance use or alcohol use.
  • You have other conditions that may make it hard for you to follow the trial requirements, or you are unable to participate on your own (confirm with trial site).
  • You have been diagnosed with an end-stage organ disease (a serious condition where a major organ is in the final stages of failure).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +12623448468

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
PGP Health
Registry
ClinicalTrials.gov
Start date
21 May 2025
Est. completion
1 May 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Incidence of intolerable treatment-related adverse events (AEs); Incidence, severity, and causal relationship of treatment-emergent AEs (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov